Upgrade to SI Premium - Free Trial

AstraZeneca (AZN) and Merck's (MRK) LYNPARZA Approved in EU for Treatment of Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer

April 10, 2019 6:46 AM
AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the European Commission has ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles